HIF1A Knockout HaCaT Cell Line

The choice depends on whether you are studying HIF1A's role as the principal hypoxia-inducible transcription factor or modeling its functions in skin biology, wound healing, and keratinocyte hypoxic responses. The Knockout line is the standard tool for asking whether HIF1α is required for these processes — HIF1α is the oxygen-regulated subunit of HIF (hypoxia-inducible factor); under normoxia, prolyl hydroxylases (PHD1/2/3) hydroxylate HIF1α at P402/P564, targeting it for VHL-mediated polyubiquitination and proteasomal degradation. Under hypoxia, HIF1α stabilizes, dimerizes with HIF1β/ARNT, and binds hypoxia response elements (HRE) to drive expression of glycolytic enzymes, VEGF, EPO, and other hypoxic adaptation genes. Overexpression is useful for studying HIF1α gain-of-function effects. For skin and wound healing research, the EDITGENE HIF1A Knockout in HaCaT is highly relevant — HaCaT is a human keratinocyte cell line, and HIF1α drives keratinocyte hypoxic responses critical for skin wound healing and skin cancer biology. HIF2α (EPAS1) paralog expression analysis aids interpretation given partial functional overlap. Rescue with wild-type, hydroxylation-resistant (P402A/P564A double mutation = constitutively stable HIF1α), or DNA-binding-deficient HIF1α enables comprehensive structure-function studies. The knockout is a critical specificity tool for HIF-stabilizing PHD inhibitors (roxadustat, daprodustat, vadadustat — FDA-approved or in development for renal anemia).

Primary applications: • Hypoxic response: HIF target gene (VEGFA, GLUT1, GAPDH, LDHA) expression analysis following hypoxia (1% O2) or DMOG/CoCl2 treatment in HIF1A-null keratinocytes. • Wound healing: scratch wound healing assays under normoxia versus hypoxia given HIF1α's role in keratinocyte wound responses. • Skin cancer biology: in heterologous skin cancer-relevant contexts, characterization of HIF1α-mediated cancer adaptation. • PHD inhibitor specificity: critical genetic control for roxadustat (FDA-approved for CKD anemia), daprodustat, vadadustat, and other PHD/HIF stabilizers — these compounds should have no effect on HIF1α target gene expression in HIF1A-null cells. EDITGENE recommends this HaCaT-based model for researchers investigating keratinocyte hypoxic responses, wound healing biology, and HIF1α-targeted therapeutic development.

Yes. HIF1A rescue experiments are well-established for hypoxia research: • Construct design: use a codon-modified HIF1A sequence with a small C-terminal tag (FLAG, HA). HIF1α has N-terminal bHLH-PAS DNA binding/dimerization, central ODD (oxygen-dependent degradation) domain with P402/P564 hydroxylation sites, and C-terminal transactivation domain — preserve all elements. • Constitutively stable rescue: P402A/P564A double mutation in the ODD hydroxylation sites bypasses PHD-VHL-mediated degradation, generating constitutively active HIF1α — invaluable for separating hypoxia-induced from constitutive HIF1α functions. • DNA-binding-deficient rescue: bHLH basic region mutations abolish HRE binding. • PHD inhibitor specificity: rescue with WT HIF1α restores PHD inhibitor (roxadustat) sensitivity, while P402A/P564A bypasses PHD regulation entirely. • Functional readout: rescue should restore hypoxia-induced HIF target gene expression (VEGFA, GLUT1, LDHA). HaCaT-specific considerations: • HaCaT is a spontaneously immortalized human keratinocyte cell line widely used for skin biology, wound healing, and keratinocyte differentiation research. • Lentiviral transduction efficiency is moderate; standard keratinocyte culture conditions are required. • HaCaT retains many keratinocyte features but may differ from primary keratinocytes in some respects — confirm relevant phenotypes in primary models when possible.